Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
Good newsThe U.S. Food and Drug Administration approved Revlimid as. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...
Lenalidomide is approved in nearly 70 countries, in combination with dexamethasone for the treatment of patients with MM who have received at least one prior therapy. Orphan indications include diffuse large B-cell lymphoma , chronic lymphocytic leukemia and mantle cell lymphoma .
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.
Another common indication for colonoscopy is the investigation of iron deficiency with or without anaemia. The examination of the colon, to rule out a lesion contributing to blood loss, along with an upper gastrointestinal endoscopy (gastroscopy) to rule out oesophageal, stomach, and proximal duodenal sources of blood loss.
Patients with mantle cell lymphoma got new hope thanks to newly approved treatments in 2013. That's good news for the 2,800 U.S. patients with MCL, a hard-to-treat disease with a significant need ...
Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). [5]In the EU, minjuvi is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell ...
After years of clinical studies, the Food and Drug Administration approved pomalidomide, now branded as Pomalyst, for treatment of relapsed or refractory multiple myeloma on Feb. 8, 2013.